Beyond NLST Findings and USPSTF Guideline
The 40 groups petitioning CMS are seeking to broaden the eligible population further to “other high risk patient populations where evidence is promising.”
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
